Enalaprilat dihydrate is the first dicarboxylate-containing ACE inhibitor with an IC50 of 4 nM. It was developed partly to overcome these limitations of captopril. The sulfhydryl-moiety was replaced by a carboxylate-moiety, but additional modifications were required in its structure-based design to achieve a similar potency to captopril.
|Cell lines||Rat cardiac fibroblasts cell lines|
|Preparation method||After 24 hours incubation in serum-free medium (DMEM), stimulating cells with IGF-I (1-100 nM) and coincubating with Enalaprilat (1 nM-10 μM) for 24 hours. Using a colorimetric immunoassay during the last 4 hours of the 24 hours incubation period to assesse cellular proliferation by 5-bromo-2'-deoxyuridine (BrdU) incorporation . Mearsuring the extinctions at 450 nm in an ELISA plate reader. All values consist of an n=9.|
|Concentrations||Dissolved in DMSO, final concentrations 1 nM - 10 μM|
|Incubation time||24 hours|
|Animal models||Male Sprague–Dawley rats|
|Formulation||Dissolved in a vehicle solution (1 mg in 950 μL of phosphate buffered saline and 50 μL 1M Na2CO3).|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO 60 mg/mL|
|Related ACE Products|
Lisinopril Dihydrate is angiotensin-converting enzyme inhibitor, used in treatment of hypertension, congestive heart failure, and heart attacks.
Lisinopril is angiotensin-converting enzyme inhibitor, used in treatment of hypertension, congestive heart failure, and heart attacks.
Zofenopril Calcium is an antioxidant that acts as an angiotensin-converting enzyme （ACE）inhibitor.
Quinapril hydrochloride is the hydrochloride salt of quinapril that is an angiotensin-converting enzyme inhibitor with a Ki of 20 μM.
Enalapril Maleate, the active metabolite of enalapril, competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.